Back
Open Access

Right-sided cardiac echocardiographic parameters show no major change during 3-months mavacamten treatment in obstructive hypertrophic cardiomyopathy

Session: What is new in hypertrophic cardiomyopathy
Topic: Myocardial Disease
Speaker: Doctor N. Schvartz (Szeged, HU)
Event: EACVI 2025

Congress Presentation

Add to my library

Like

About the speaker

Doctor Noemi Schvartz

University of Szeged, Szeged (Hungary)
0 follower

6 more presentations in this session

Innovative markers of left atrial remodeling in the prediction of exercise capacity in sarcomeric hypertrophic cardiomyopathy

Speaker: Mr A. Melot (Rennes, FR)

Access
Abstract
Like
Thumbnail

Echocardiographic parameters of left ventricular diastolic dysfunction, left atrial volumes and left atrial function improves in obstructive hypertrophic cardiomyopathy during mavacamten treatment

Speaker: Doctor A. Kormanyos (Szeged, HU)

Access
Abstract
Like
Thumbnail

Echocardiographic drag effect index predicts response to mavacamten in obstructive hypertrophic cardiomyopathy

Speaker: Doctor J. Ha (Seoul, KR)

Access
Abstract
Like
Thumbnail

Left atrial total emptying fraction is the main predictor of atrial fibrillation in patients with hypertrophic cardiomyopathy

Speaker: Doctor I. Cergan (Bucharest, RO)

Access
Abstract
Like
Thumbnail

Echocardiographic changes with mavacamten in patients with obstructive hypertrophic cardiomyopathy: early experience from a referral center

Speaker: Doctor L. Videla (Barcelona, ES)

Access
Abstract
Like
Thumbnail

Access the full session

What is new in hypertrophic cardiomyopathy

Speakers: Doctor N. Schvartz, Mr A. Melot, Doctor A. Kormanyos, Doctor J. Ha, Doctor I. Cergan...
Access
Like
Thumbnail

About the event

Image

EACVI 2025

11 December - 13 December 2025

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

bristol-myers-squibb Explore sponsored resources
novartis Explore sponsored resources